Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors
Primary Purpose
Globus
Status
Completed
Phase
Phase 3
Locations
Thailand
Study Type
Interventional
Intervention
Omeprazole
psychoeducation
Flupentixol +Melitracen
Sponsored by
About this trial
This is an interventional treatment trial for Globus
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years
Symptoms based on the following criteria: Persistent or intermittent nonpainful sensation of a lump or foreign body in the throat with no structural lesion identified on physical examination, laryngoscopy, or endoscopy.
- Occurrence of the sensation between meals.
- Absence of dysphagia or odynophagia
Exclusion Criteria:
- Subjects with psychological disease
- Significant heart disease and/or arrhythmia
- Proton Pump inhibitors and/or Histamine 2 Receptor Antagonist use within 2 weeks before randomization
- Mono-amine Oxidase inhibitors or Selective Serotonin Reuptake Inhibitor or Tricyclic antidepressant use within 2 weeks before randomization
- History of drug allergy that use in research
- Pregnancy or breast feeding
- Decline to participate in study
Sites / Locations
- Division of gastroenterology, Department of Medicine, Siriraj hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
Flupentixol + Melitracen & placebo
Proton pump inhibitor & placebo
Psychoeducation&placebo
Arm Description
Deanxit® (Flupentixol + Melitracen) 5 mg/D*4 weeks will be given
Miracid® (Omeprazole) 20 mg/D*4 weeks will be given
Psychoeducation by psychologists will be advised on Day 1 and Day 14 of the study time frame
Outcomes
Primary Outcome Measures
Clinical improvement
Change in clinical scores assessed by Glasgow-Edinburgh throat Scale from baseline to the endo of the study
Secondary Outcome Measures
Improvement in quality of life
Changes in the scores assessed by the 36-Item Short Form Health Survey questionnaire from baseline to the end of the study.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03205228
Brief Title
Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors
Official Title
Treatment Outcomes in Patients With Globus: A Randomized Control Trial of Psychoeducation, Anxiolytics and Proton Pump Inhibitors
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
July 7, 2017 (Actual)
Primary Completion Date
June 26, 2018 (Actual)
Study Completion Date
July 28, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mahidol University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A randomized controlled trial study is conducted to compare treatment efficacy between psycho-education, anxiolytics drug and proton pump inhibitors in participants who met the criteria of globus.
Detailed Description
This is a randomized controlled trial in patients with globus. All participants will be allocated into 3 groups (16 subjects/group) : Proton pump inhibitors (miracid®) , anxiolytics drug (Deanxit®) and psycho-education. The study duration is 4 weeks long.
Data regarding clinical severity and quality of life of all participants will be collected at the beginning and at the end of treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Globus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Flupentixol + Melitracen & placebo
Arm Type
Experimental
Arm Description
Deanxit® (Flupentixol + Melitracen) 5 mg/D*4 weeks will be given
Arm Title
Proton pump inhibitor & placebo
Arm Type
Active Comparator
Arm Description
Miracid® (Omeprazole) 20 mg/D*4 weeks will be given
Arm Title
Psychoeducation&placebo
Arm Type
Active Comparator
Arm Description
Psychoeducation by psychologists will be advised on Day 1 and Day 14 of the study time frame
Intervention Type
Drug
Intervention Name(s)
Omeprazole
Other Intervention Name(s)
Miracid®
Intervention Description
A capsule of Omeprazole 20 mg & 1 capsule of placebo will be given in individual subject, once daily for 4 weeks. Both drugs will be presented in the same appearance (white capsule).
Intervention Type
Behavioral
Intervention Name(s)
psychoeducation
Other Intervention Name(s)
advice for symptoms management
Intervention Description
Psychoeducation will be given by psychologists at the Day 1 and Day 15 of the study period.One white capsule of placebo will be given once daily for 4 weeks of the study period.
Intervention Type
Drug
Intervention Name(s)
Flupentixol +Melitracen
Other Intervention Name(s)
Deanxit®
Intervention Description
A capsule containing of a tablet of melitracen 10 mg + flupentixol 0.5 mg & a capsule of placebo will be given once daily, for 4 weeks. Both would be presented in the same appearance (white capsule)
Primary Outcome Measure Information:
Title
Clinical improvement
Description
Change in clinical scores assessed by Glasgow-Edinburgh throat Scale from baseline to the endo of the study
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Improvement in quality of life
Description
Changes in the scores assessed by the 36-Item Short Form Health Survey questionnaire from baseline to the end of the study.
Time Frame
28 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years
Symptoms based on the following criteria: Persistent or intermittent nonpainful sensation of a lump or foreign body in the throat with no structural lesion identified on physical examination, laryngoscopy, or endoscopy.
Occurrence of the sensation between meals.
Absence of dysphagia or odynophagia
Exclusion Criteria:
Subjects with psychological disease
Significant heart disease and/or arrhythmia
Proton Pump inhibitors and/or Histamine 2 Receptor Antagonist use within 2 weeks before randomization
Mono-amine Oxidase inhibitors or Selective Serotonin Reuptake Inhibitor or Tricyclic antidepressant use within 2 weeks before randomization
History of drug allergy that use in research
Pregnancy or breast feeding
Decline to participate in study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Monthira Maneerattanaporn, MD., MS.
Organizational Affiliation
Mahidol University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Division of gastroenterology, Department of Medicine, Siriraj hospital
City
Bangkok Noi
State/Province
Bangkok,
ZIP/Postal Code
10700
Country
Thailand
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors
We'll reach out to this number within 24 hrs